Cargando…

Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Marcelo H, Satoh, Minoru, Martin-Marquez, Beatriz T, Vargas-Ramírez, Raul, Jara, Luis J, Saavedra, Miguel A, Cruz-Gonzalez, Claudia, Andrade-Ortega, Lilia, Vera-Lastra, Olga, Salazar-Páramo, Mario, Prieto-Parra, Rosa E, Gonzalez-Lopez, Laura, Gamez-Nava, Jorge I, Ramírez-Sánchez, Hermes U, Chan, Jason YF, Ross, Steven J, Chan, Edward KL, Vázquez-Del Mercado, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060281/
https://www.ncbi.nlm.nih.gov/pubmed/23557279
http://dx.doi.org/10.1186/ar4207
_version_ 1782321350985121792
author Petri, Marcelo H
Satoh, Minoru
Martin-Marquez, Beatriz T
Vargas-Ramírez, Raul
Jara, Luis J
Saavedra, Miguel A
Cruz-Gonzalez, Claudia
Andrade-Ortega, Lilia
Vera-Lastra, Olga
Salazar-Páramo, Mario
Prieto-Parra, Rosa E
Gonzalez-Lopez, Laura
Gamez-Nava, Jorge I
Ramírez-Sánchez, Hermes U
Chan, Jason YF
Ross, Steven J
Chan, Edward KL
Vázquez-Del Mercado, Mónica
author_facet Petri, Marcelo H
Satoh, Minoru
Martin-Marquez, Beatriz T
Vargas-Ramírez, Raul
Jara, Luis J
Saavedra, Miguel A
Cruz-Gonzalez, Claudia
Andrade-Ortega, Lilia
Vera-Lastra, Olga
Salazar-Páramo, Mario
Prieto-Parra, Rosa E
Gonzalez-Lopez, Laura
Gamez-Nava, Jorge I
Ramírez-Sánchez, Hermes U
Chan, Jason YF
Ross, Steven J
Chan, Edward KL
Vázquez-Del Mercado, Mónica
author_sort Petri, Marcelo H
collection PubMed
description INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico. METHODS: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies were characterized by immunoprecipitation using (35)S-methionine labeled K562 cell extract. Clinical information was obtained from medical records. RESULTS: DM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140 was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86% versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase (CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy. CONCLUSIONS: Anti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK. The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production.
format Online
Article
Text
id pubmed-4060281
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40602812014-06-17 Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara Petri, Marcelo H Satoh, Minoru Martin-Marquez, Beatriz T Vargas-Ramírez, Raul Jara, Luis J Saavedra, Miguel A Cruz-Gonzalez, Claudia Andrade-Ortega, Lilia Vera-Lastra, Olga Salazar-Páramo, Mario Prieto-Parra, Rosa E Gonzalez-Lopez, Laura Gamez-Nava, Jorge I Ramírez-Sánchez, Hermes U Chan, Jason YF Ross, Steven J Chan, Edward KL Vázquez-Del Mercado, Mónica Arthritis Res Ther Research Article INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico. METHODS: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies were characterized by immunoprecipitation using (35)S-methionine labeled K562 cell extract. Clinical information was obtained from medical records. RESULTS: DM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140 was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86% versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase (CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy. CONCLUSIONS: Anti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK. The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production. BioMed Central 2013 2013-04-04 /pmc/articles/PMC4060281/ /pubmed/23557279 http://dx.doi.org/10.1186/ar4207 Text en Copyright © 2013 Petri et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Petri, Marcelo H
Satoh, Minoru
Martin-Marquez, Beatriz T
Vargas-Ramírez, Raul
Jara, Luis J
Saavedra, Miguel A
Cruz-Gonzalez, Claudia
Andrade-Ortega, Lilia
Vera-Lastra, Olga
Salazar-Páramo, Mario
Prieto-Parra, Rosa E
Gonzalez-Lopez, Laura
Gamez-Nava, Jorge I
Ramírez-Sánchez, Hermes U
Chan, Jason YF
Ross, Steven J
Chan, Edward KL
Vázquez-Del Mercado, Mónica
Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title_full Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title_fullStr Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title_full_unstemmed Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title_short Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
title_sort implications in the difference of anti-mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from mexico city and guadalajara
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060281/
https://www.ncbi.nlm.nih.gov/pubmed/23557279
http://dx.doi.org/10.1186/ar4207
work_keys_str_mv AT petrimarceloh implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT satohminoru implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT martinmarquezbeatrizt implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT vargasramirezraul implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT jaraluisj implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT saavedramiguela implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT cruzgonzalezclaudia implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT andradeortegalilia implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT veralastraolga implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT salazarparamomario implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT prietoparrarosae implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT gonzalezlopezlaura implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT gameznavajorgei implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT ramirezsanchezhermesu implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT chanjasonyf implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT rossstevenj implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT chanedwardkl implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara
AT vazquezdelmercadomonica implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara